Clinical Trials
29 trialsMK-2140-010
Merck Sharp & Dohme LLC
MK-2140-011
Merck Sharp & Dohme LLC
OLYMPIA-3
Regeneron Pharmaceuticals
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco
REMoDL-A
University Hospital Southampton NHS Foundation Trust
INCA
University College, London
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Dana-Farber Cancer Institute
HO170DLBCL
Stichting Hemato-Oncologie voor Volwassenen Nederland
Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma
Barbara Ann Karmanos Cancer Institute
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Zhejiang Teruisi Pharmaceutical Inc.
R-CMOP in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma
University of Nebraska
COALITION
Peter MacCallum Cancer Centre, Australia
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
Ipsen
The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high Risk Diffuse Large B-cell Lymphoma Who Had Incomplete Remission.
The First Hospital of Jilin University
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
STELLAR
University of Birmingham
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL
Kosin University Gospel Hospital
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.
Erythropoietin for Management of Anemia Caused by Chemotherapy
Kosin University Gospel Hospital
A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a
Hoffmann-La Roche
REMoDL-B
University Hospital Southampton NHS Foundation Trust
Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
University College, London
Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
NHL-14
Arbeitsgemeinschaft medikamentoese Tumortherapie
Combination Chemotherapy in Treating Older Patients With Intermediate- or High-Grade Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
National Cancer Institute (NCI)
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
Asan Medical Center
Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma
National Cancer Institute (NCI)